Ca2+/CaM-Dependent Protein Kinase II: A Novel Target in Heart Failure
Ca2 /CaM 依赖性蛋白激酶 II:心力衰竭的新靶点
基本信息
- 批准号:8122706
- 负责人:
- 金额:$ 21.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-06-15 至 2013-05-31
- 项目状态:已结题
- 来源:
- 关键词:Active SitesAnimal ModelApoptosisBindingBiochemicalCalciumCalcium/calmodulin-dependent protein kinaseCardiacCardiac MyocytesCardiac OutputCardiovascular PhysiologyCatalytic DomainChemicalsClinicalDockingEnsureEventFunctional disorderGeneticGoalsHeart DiseasesHeart failureHomeostasisHypertrophyIn SituIn VitroInhibitory Concentration 50Ion ChannelKnock-outLeadMetabolicMolecular ModelsMusNeonatalPatientsPharmaceutical ChemistryPharmaceutical PreparationsPhasePhosphorylationPhosphotransferasesPositioning AttributePropertyProtein IsoformsProtein Kinase InhibitorsReagentResearchScientistSignal TransductionSolubilityStagingStructureSudden DeathSyndromeSynthesis ChemistryTestingTimeLineanalogbasecalmodulin-dependent protein kinase IIdesignefficacy testingimprovedin vitro Assayinhibitor/antagonistinsightlifetime riskmeetingsmolecular modelingnovelpre-clinicalprotein kinase inhibitorprototypesensorsmall molecule
项目摘要
DESCRIPTION (provided by applicant): Heart disease converts to the clinical syndrome of heart failure when the cardiac output is inadequate to meet metabolic requirements. Evidence now supports that pharmacological targeting of Ca2???? dependent protein kinase II (CaMKII), a sensor of dysregulated calcium homeostasis, will inhibit conversion of early stages of cellular pathophysiology to symptomatic heart failure and sudden death. Inhibition of the kinase with research inhibitors, or by genetic knock-out of the major cardiac isoform, blocks this chain of events in animal models. We propose a strategy to modify a small molecule inhibitor of CaMKII to increase its potency and selectivity, test it biochemically to ensure it has the desired mechanism of action, then test for inhibition of characterized markers of hypertrophy and for apoptosis in neonatal mouse cardiomyocytes. We start with an allosteric CaMKII inhibitor used to demonstrate its cardiovascular functions but has never been pharmacologically optimized and thus have low potency. Guided by our analysis of new crystal structures and structural insights we have developed from docking inhibitors to its active site we have designed a set of compounds that target a unique feature of the allosteric pocket in the active site of CaMKII. Our overall goals for Phase I are to retain and improve the selectivity of the inhibitor while markedly increasing its potency, and to test the lead inhibitor compounds for efficacy then test for inhibition of characterized markers of hypertrophy and for apoptosis it in neonatal mouse cardiomyocytes
PUBLIC HEALTH RELEVANCE: Heart failure is a global burden, with the lifetime risk in the developed world above 20% and a consuming focus for patients, clinicians, scientists, and policymakers. Heart disease converts to the clinical syndrome of heart failure when the cardiac output is inadequate to meet metabolic requirements. Evidence now supports that pharmacological targeting of intracellular signaling, in particular of Ca2???? dependent protein kinase II, a sensor of dysregulated calcium homeostasis will inhibit conversion to symptomatic heart failure and sudden death. We propose a strategy to modify a small molecule inhibitor of this protein kinase in ways that increase its potency, analyze it biochemically to ensure it has the desired mechanism of action, then test for inhibition of characterized markers of hypertrophy and for apoptosis it in neonatal mouse cardiomyocytes.
描述(由申请方提供):当心输出量不足以满足代谢要求时,心脏病转化为心力衰竭的临床综合征。现在的证据支持药理学靶向钙离子依赖性蛋白激酶II(CaMKII),钙稳态失调的传感器,将抑制细胞病理生理学的早期阶段向有症状的心力衰竭和猝死的转化。用研究抑制剂抑制激酶,或通过基因敲除主要的心脏亚型,阻断了动物模型中的这一事件链。我们提出了一种策略,修改CaMKII的小分子抑制剂,以增加其效力和选择性,测试它的生化,以确保它具有所需的作用机制,然后测试抑制肥大的特征标记物和新生小鼠心肌细胞的凋亡。我们从一种用于证明其心血管功能的变构CaMKII抑制剂开始,但从未进行过优化,因此效力较低。通过我们对新晶体结构和结构见解的分析,我们已经从对接抑制剂开发到其活性位点,我们设计了一组化合物,这些化合物针对CaMKII活性位点中变构口袋的独特功能。我们I期的总体目标是保持和提高抑制剂的选择性,同时显著提高其效力,并测试先导抑制剂化合物的功效,然后测试其对肥大的特征性标志物的抑制以及新生小鼠心肌细胞的凋亡
公共卫生相关性:心力衰竭是一个全球性负担,在发达国家的终生风险超过20%,是患者、临床医生、科学家和政策制定者关注的焦点。当心输出量不足以满足代谢要求时,心脏病转化为心力衰竭的临床综合征。现在的证据支持,药理学靶向细胞内信号,特别是钙离子?依赖性蛋白激酶II,钙稳态失调的传感器,将抑制转化为有症状的心力衰竭和猝死。我们提出了一种策略,以增加其效力的方式修改这种蛋白激酶的小分子抑制剂,对其进行生物化学分析以确保其具有所需的作用机制,然后测试其在新生小鼠心肌细胞中抑制肥大的特征性标志物和凋亡。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Howard Schulman其他文献
Howard Schulman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Howard Schulman', 18)}}的其他基金
Targeting CaM Kinase II for Neuroprotection in Ischemic Stroke
靶向 CaM 激酶 II 对缺血性中风的神经保护
- 批准号:
8251625 - 财政年份:2012
- 资助金额:
$ 21.29万 - 项目类别:
Gating the activation and tuning the Ca2+ frequency response of CaM kinase II
门控 CaM 激酶 II 的激活并调节 Ca2 频率响应
- 批准号:
8737282 - 财政年份:2012
- 资助金额:
$ 21.29万 - 项目类别:
Gating the activation and tuning the Ca2+ frequency response of CaM kinase II
门控 CaM 激酶 II 的激活并调节 Ca2 频率响应
- 批准号:
8550104 - 财政年份:2012
- 资助金额:
$ 21.29万 - 项目类别:
Gating the activation and tuning the Ca2+ frequency response of CaM kinase II
门控 CaM 激酶 II 的激活并调节 Ca2 频率响应
- 批准号:
8276424 - 财政年份:2012
- 资助金额:
$ 21.29万 - 项目类别:
Ca2+/CaM-Dependent Protein Kinase II: A Novel Target in Osteosarcoma
Ca2 /CaM 依赖性蛋白激酶 II:骨肉瘤的新靶点
- 批准号:
8251055 - 财政年份:2012
- 资助金额:
$ 21.29万 - 项目类别:
Developing Ca2+/CaM Kinase II Inhibitors to Treat Arrhythmias in Heart Failure
开发 Ca2/CaM 激酶 II 抑制剂来治疗心力衰竭引起的心律失常
- 批准号:
8393257 - 财政年份:2012
- 资助金额:
$ 21.29万 - 项目类别:
Targeting CaM Kinase II and Oxidative Damage in Allergic Asthma
针对过敏性哮喘中的 CaM 激酶 II 和氧化损伤
- 批准号:
8201775 - 财政年份:2011
- 资助金额:
$ 21.29万 - 项目类别:
Advancing Proteomic Analysis of CSF in Nervous System Diseases
推进神经系统疾病脑脊液的蛋白质组学分析
- 批准号:
8038538 - 财政年份:2009
- 资助金额:
$ 21.29万 - 项目类别:
Proteomic Biosignatures of Chronic Drug Exposure
慢性药物暴露的蛋白质组生物特征
- 批准号:
8008725 - 财政年份:2009
- 资助金额:
$ 21.29万 - 项目类别:
Proteomic Biosignatures of Chronic Drug Exposure
慢性药物暴露的蛋白质组生物特征
- 批准号:
7772366 - 财政年份:2009
- 资助金额:
$ 21.29万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 21.29万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 21.29万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 21.29万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 21.29万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 21.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 21.29万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 21.29万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 21.29万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 21.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 21.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists